However, much is still unknown regarding the impact of splenectomy on the outcome of allo-SCT. Previous work has suggested an association between acute and chronic GVHD and splenectomy prior to allo-SCT. 3, 4 Conversely, more recent work failed to see this correlation and instead showed an association between splenectomy and relapse after CML. 5, 6 In a recent 'Center for International Blood and Marrow Transplant Research' (CIBMTR) report, the authors analyzed the effects of spleen status on engraftment and other early outcomes after allo-SCT. 7 In this material, over 9000 patients were transplanted with myeloablative conditioning (MAC) and the authors showed a decrease in time of neutrophil and platelet engraftment in patients with splenectomy compared to individuals with normal spleen status. However, when analyzing other complications or the OS of the patient cohort no difference was observed between individuals with and those without a spleen.
We have, in an earlier retrospective analysis of risk factors for EBV-associated post-transplant proliferative disease (EBV-PTLD), identified splenectomy as a significant risk factor. 8 In regard to the CIBMTR study above, we decided to perform a retrospective analysis of the impact of splenectomy on clinical outcome in patients transplanted at Karolinska between 1995 and 2012 ( Table 1) . Of all the clinical parameters analyzed after allo-SCT, the only incident that was significantly different between patients with or without splenectomy was the occurrence of PTLD (Table 1) . No difference could be observed regarding TRM or OS.
In a multivariate analysis, including parameters that were significantly different between the two patient groups (Table 1) , splenectomy was the only factor significantly associated with PTLD (P ¼ 0.01; Table 2 ).
Our finding might argue for a distinct role of the spleen in the control of EBV-PTLD. The spleen is an important part of the immune system, especially regarding humoral immunity. In addition to T-cell immunity, little is known regarding B cells and immunoglobulins in the defense against EBV. 9 Recent studies have re-discovered other B-cell-related functions that might be of importance for EBV control (reviewed in the study by Mauri and Bosma 10 ). Certain B-cell subpopulations, for example CD5 þ B-1 cells, reside almost exclusively in the spleen. One of the functions for this B-cell population is its important immune regulatory function.
11 A potential scenario is that CD5 þ maintenance is impaired in patients after splenectomy and the regulatory B-cell function may be impaired resulting in increased EBV-blast expansion.
There are obvious differences between our patient material and the large cohort presented by Akpek et al. 7 Our material is a mix of patients treated with MAC and RIC. The CIBMTR study only consists of MAC patients. RIC has previously been associated with an increased risk of EBV-PTLD. 8 In addition, a vast majority of our patients are treated with ATG, which is also a known risk factor for EBV-PTLD due to an increase in inhibition of T-cell-mediated EBV control. 8 These two factors might very well increase the likelihood for EBV-PTLD compared to the large multi-center material presented by Akpek et al. 7 Finally, in the CIBMTR-report all viral diseases were grouped together possibly masking a change in the frequency of EBV-PTLD alone. 
